Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

When Global ART Budgets Cannot Cover All Patients, Who Should Be Eligible?

Zhang, Yi, ABa; Bärnighausen, Till, MD, PhDb,c,d; Eyal, Nir, DPhild

JAIDS Journal of Acquired Immune Deficiency Syndromes: June 1, 2019 - Volume 81 - Issue 2 - p 134–137
doi: 10.1097/QAI.0000000000002017
Critical Review
Buy
SDC

Background: Widely expected cuts to budgets for global HIV/AIDS response force hard prioritization choices.

Setting: We examine policies for antiretroviral therapy (ART) eligibility through the lens of the most relevant ethical approaches.

Methods: We compare earlier ART eligibility to later ART eligibility in terms of saving the most lives, life-years, and quality-adjusted life-years, special consideration for the sickest, special consideration for those who stand to benefit the most, special consideration for recipients' own health needs, and special consideration to avoid denying ART permanently.

Results: We argue that, in most low- and middle-income countries with generalized HIV/AIDS epidemic, ethically, ART for sicker patients should come before ART eligibility for healthier ones immediately on diagnosis (namely, before “universal test and treat”). In particular, reserving all ART for sicker patients would usually save more life-years, prioritize the sickest, and display other properties that some central ethical approaches find important, and that concern none—so ethically, it is “cross-theoretically dominant,” as we put it.

Conclusions: In most circumstances of depressed financing in low- and middle-income countries with generalized HIV/AIDS epidemic, reserving all ART for sicker patients is more ethical than the current international standard.

aStanford University School of Medicine, Stanford, CA;

bHeidelberg Institute of Global Health, University of Heidelberg, Heidelberg, Germany;

cAfrica Health Research Institute, KwaZulu Natal, South Africa; and

dDepartment of Global Health and Population, Harvard T. H. Chan School of Public Health, Boston, MA.

Correspondence to: Yi Zhang, Stanford University School of Medicine, 300 Pasteur Dr, Stanford, CA 94305 (e-mail: yizhang9@stanford.edu).

Supported by the National Institute of Allergy and Infectious Diseases (Grant number R01AI114617).

The authors have no conflicts of interest to disclose.

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.

Received October 19, 2018

Accepted January 24, 2019

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.